Last reviewed 2026-04-20 · How we verify

M.V.I. Pediatric (RETINOL)

M.V.I. Pediatric (RETINOL), marketed by Pfizer, is a vitamin A supplement primarily indicated to reduce underarm wetness, positioning it in a niche market segment. Its key strength lies in its essential role in maintaining skin, vision, and immune function, differentiating it from same-class competitors like betacarotene. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

• Reduces underarm wetness

Common side effects

No common side effects on file.

Key clinical trials

• Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma (PHASE1)
• Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
• Virtual Reality and Computerized Cognitive Intervention for Mild Cognitive Impairment in Heart Failure (NA)
• Effect of the Consumption of Cookies Enriched With Plant Proteins and of a Vitamin D Supplement on the Progression of Sarcopenia in the Elderly (NA)
• Pilot Trial of Supplemental Vitamin A and Nicotinamide (EARLY_PHASE1)
• Combination of Oral and Topical Whitening Agents for Reducing Skin Pigmentation (NA)
• Child Health, Agriculture and Integrated Nutrition (NA)
• Microbiome and Health Indicators in People With Obesity, Prediabetes and Type 2 Diabetes Undergoing a Lifestyle Intervention (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.